The human T cell leukemia/lymphotropic virus-1 (HTLV-I) is the etiologic agent of adult T cell leukemia (ATL), an aggressive and fatal leukemia of CD4+ T lymphocytes. Interferon regulatory factor-4 (IRF-4) was shown previously to be constitutively expressed in T cells infected with HTLV-1. In this study, we investigated the role of IRF-4 gene regulation in the context of HTLV-1 infection using gene array technology and IRF-4 expressing T cells. Many potential IRF-4 regulated genes were identified, the vast majority of which were repressed by IRF-4 expression. Cyclin B1, a G2-M checkpoint protein identified as an IRF-4 repressed gene in the array, was further characterized in the context of HTLV-1 infection. All HTLV-1 infected cell lines and ATL patient lymphocytes demonstrated a dramatic decrease in cyclin B1 levels; subsequent analysis of the cyclin B1 promoter identified two sites important in IRF-4 binding and repression of cyclin B1 expression. Furthermore, IRF-4-mediated repression of cyclin B1 led to a significant decrease in CDC2 kinase activity in HTLV-1 infected T cells. IRF-4 expression in HTLV-1 infected T cells also downregulated other genes implicated in the mitotic checkpoint as well as genes involved in actin cytoskeletal rearrangement, DNA repair, apoptosis, metastasis and immune recognition. Several of the identified genes are dysregulated in ATL and may provide important mechanistic information concerning pathways critical to the emergence of ATL.
Introduction
The human T cell leukemia/lymphotrophic virus-1 is the etiologic agent of adult T cell leukemia (ATL), an aggressive and fatal leukemia of CD4+ T lymphocytes and is also associated with a neurological demyelinating disease, tropical spastic paraparesis (TSP) or HTLV-1 Associated Myelopathies (HAM). ATL and HAM/TSP are geographically localized to regions of the world where HTLV infection is endemic, notably southern Japan, sub-Saharan Africa, the Caribbean basin and the southwestern United States (Edlich et al., 2000; Tsukasaki et al., 2000; Yoshida, 2001 ). At present, it is estimated that between 10 and 20 million people worldwide are infected with HTLV. Treatments for ATL are ineffective; conventional chemotherapeutic treatments provide at most a 5% 4-year survival rate (Cann and Chen, 1996; Ohshima et al., 1999) . Once diagnosed with acute ATL, the median survival time is in the order of a few months (Edlich et al., 2000; Tsukasaki et al., 2000) .
Based on the phenotype of ATL cells in vivo and HTLV-1 transformed T cell lines, infection of CD4+ T cells initiates a multi-step oncogenic process that is characterized by an early proliferation of HTLV-1 infected T cells, resulting in polyclonal expansion of infected cells. Over a period of decades in vivo, a growth factor independent, monoclonal population of leukemic T cells emerges, likely as a consequence of the rapid growth of a single leukemic clone bearing multiple mutations in oncogenes and/or tumor suppressor genes (Yao and Wigdahl, 2000; Yoshida, 2001) . The oncogenic potential of HTLV-1 resides in part in the viral Tax protein, a positive regulator of viral gene transcription which disrupts cell cycle control, gene transcription and signal transduction via proteinprotein interactions (Hiscott et al., 2001; Neuveut and Jeang, 2002; Yoshida, 2001) . One of the targets of Tax is the NF-kB/IkB factors which control immune and growth regulatory gene transcription (Israel, 2000; Karin, 1999a,b) . The ability of Tax to stimulate NFkB activity occurs via activation of the signaling cascade controlling IkB phosphorylation specifically through interaction with IKKg subunit of the IkB kinase complex (Chu et al., 1999; Sun et al., 2000; . These molecular events culminate in transcriptional dysregulation in HTLV-1 infected cells, leading to CD4+ T cell proliferation that predisposes to ATL development (Yao and Wigdahl, 2000; Yoshida, 2001) .
Interestingly, one of the members of the interferon regulatory factor (IRF) family -IRF-4 -was shown to be highly expressed in cells derived from patients with ATL and in HTLV-1 infected cell lines (Imaizumi et al., 2001; Mamane et al., 1999 Mamane et al., , 2000 Mamane et al., , 2002 Sharma et al., 2000 Sharma et al., , 2002 Yamagata et al., 1996) . IRF-4 deficient mice develop severe phenotypes of immunodeficiencies (Mittrucker et al., 1997) . Both B-and Tcell activation are profoundly affected: serum immunoglobulin concentrations and antibody responses are decreased and cytotoxic and antitumor responses are absent. Thus IRF-4 appears to be essential for the function and homeostasis of both mature B and T lymphocytes (Mittrucker et al., 1997) . A detailed analysis of IRF-4 transcriptional regulation within the context of HTLV-1 infection has implicated the viral Tax protein in mediating chronic activation of the Sp1, NF-kB and NF-AT pathways leading to the overexpression of IRF-4 in ATL cells (Grumont and Gerondakis, 2000; Sharma et al., 2000 Sharma et al., , 2002 .
The role of IRF-4 per se in HTLV-1-induced leukemogenesis remains unclear. However, the relationship between IRF-4 expression and oncogenicity is highlighted by the observation that in some patients with multiple myeloma, a chromosomal translocation -t(6;14)(p25;q32) -juxtaposes the immunoglobulin heavy-chain locus to MUM1 (multiple myeloma 1); the MUM1 locus at 6p25 is identical to IRF-4. This chromosomal translocation involving IRF-4 may thus contribute to leukemogenesis since IRF-4 has oncogenic activity in vitro (Iida et al., 1997) . Recently, high levels of IRF-4 have also been identified in lymphocytes of patients with primary effusion lymphoma (Carbone et al., , 2001 Gaidano and Carbone, 2000; Iida et al., 1997; Schmidt et al., 2000) . IRF-4 was also shown to act synergistically with the v-Rel oncogene to transform fibroblasts (Hrdlickova et al., 2001) . Interestingly, a recent report also suggests that IRF-4 expression increases during the development of ATL, with IRF-4 expression levels highest during the late and ultimately fatal, acute phase of ATL (Imaizumi et al., 2001) .
Previous studies have characterized the transcriptional role of IRF-4 in lymphoid and myeloid cells. IRF-4 is involved with PU.1 in the transcriptional regulation of B cell specific genes such as immunoglobulin k and g light chains, CD20 and CD23 (Brass et al., 1996; Eisenbeis et al., 1995; Gupta et al., 1999 Gupta et al., , 2001 Himmelmann et al., 1997; Meraro et al., 1999; Nagulapalli and Atchison, 1998) . IRF-4 transactivating complexes are also involved in the regulation of IL-1b and ISG15 in macrophages (Marecki et al., 2001; Rosenbauer et al., 1999) . Since IRF-4/PU.1 heterocomplexes are specific to B cells and macrophages, IRF-4 may be acting on its own or with another unidentified partner in T cells Marecki and Fenton, 2000) . Interestingly, the role of IRF-4 in HTLV-I induced leukemogenesis remains to be elucidated. In this study, the role of IRF-4 in T cells was investigated using an IRF-4 stably expressing Jurkat T cell line and cDNA array technology. We demonstrated that many cell growth and homeostasis related genes are repressed by IRF-4 expression, including the transcriptional downregulation of cyclin B1.
Results

IRF-4 stably expressing Jurkat cell line
The IRF-4 stably expressing Jurkat T cell line (Jurkat-MSCV-IRF-4) was obtained using the pMSCV neo system (Clontech) with a Phoenix amphotropic packaging cell line. After selection with G418, whole cell extracts from the Jurkat-MSCV-IRF-4, Jurkat-MSCV and non-transduced Jurkat cells were analysed for IRF-4 expression by immunoblot. Higher levels of IRF-4 were detected in the Jurkat-MSCV-IRF-4 cells after neomycin selection whereas IRF-4 was not expressed in either Jurkat or Jurkat-MSCV (Figure 1 , lanes 1 -3, lanes 4 -6 and lane 7, respectively).
cDNA array analysis of IRF-4 regulated genes 32 P-labeled cDNA probes were generated from total RNA extracted from the Jurkat-MSCV-IRF-4 cells and the control Jurkat-MSCV cells. Three separate experiments (RNA extraction, probe synthesis and hybridization) were performed on two separate Atlas Human 1.2 Arrays to identify IRF-4 target genes in T cells (Table 1) . Out of the 1176 genes analysed, 47 were significantly decreased (41.5-fold) in at least two of the three experiments (Table 1) . Some genes were also increased but the fold induction was rarely over 1.5 (data not shown) indicating that IRF-4 functions in a T cell context predominantly as a repressor of gene expression. Downregulated genes belong to multiple Figure 1 An IRF-4 stably expressing Jurkat T cell line used in cDNA array analysis. An IRF-4 stably expression Jurkat cell line was produced using the pMSCV neo system with an amphotropic packaging cell line. IRF-4 was subcloned into pMSCV neo plasmid and transiently transfected into the amphotropic packaging cell line. As a control, pMSCV wt neo plasmid was also transiently transfected in the packaging cell line. Forty-eight hours post-transfection, virus-containing media was collected and used to infect Jurkat T cells. Forty-eight hours post-infection, aliquots from the IRF-4 infected Jurkat cells as well as wt infected cells were analysed for IRF-4 expression by Western blot. WCE (100 mg) were run on 10% SDS -PAGE and blotted with an a-IRF-4 antibody. The rest of the cells were put under antibiotic selection using neomycin for two weeks. After selection, increasing amount of whole cell extracts (25, 50 and 100 mg) from the Jurkat-MSCV-IRF-4 cells, the Jurkat-MSCV cells as well as untransduced Jurkats were analysed by Western blot using an a-IRF-4 antibody IRF-4 regulated genes in HTLV-1 infected T cells Y Mamane et al functional categories such as intracellular protein kinases, G proteins, tumor suppressors, cell cycle regulators, replication and repair factors, apoptosis related proteins, transcription factors and cell surface antigens (Table 1) .
To confirm the results of the cDNA arrays, expression of selected genes was further analysed at the RNA and protein levels. RT -PCR analysis was performed on RNA extracted from Jurkat-MSCV, Jurkat-MSCV-IRF-4 and the HTLV-I transformed CD4+ T cell line, MT2 ( Figure 2a ). As expected, most of the mRNAs downregulated in the cDNA array experiments were also downregulated by RT -PCR in the Jurkat-MSCV-IRF-4. Interestingly, the same genes were also consistently downregulated in the MT2 cells. One exception was the expression pattern of CXCR4 mRNA in MT2 cells. CXCR4 mRNA was upregulated in the HTLV-1 infected T cells compared to Jurkat-MSCV (Figure 2a ), indicating that IRF-4 gene regulation may be modulated differently depending on the cellular context. Fold increase or decrease in mRNA expression was calculated relative to the amount of GAPDH amplified in each cell line. Protein extracts were also quantified in these cell lines by immunoblot and the results in general agreed with the data obtained by RT -PCR ( Figure 2b ). As expected, Genes down-regulated by IRF-4. Three separate experiments (RNA extraction, probe synthesis and hybridization) were performed using the Jurkat-MSCV-IRF-4 and the Jurkat-MSCV cells to determine the genes regulated by IRF-4. The average fold decrease is listed in the table.
Underlined genes were further analysed by RT -PCR and immunoblot in Figure 2 . Genes highlighted in italics are described further in the Discussion P]dCTP. Samples (5 ml) were loaded on 4% polyacrylamide gels, dried and exposed to film. Results from at least two separate RT -PCRs were quantified using the NIH Image 1.60 program. The results were also quantified relative to the amount of GAPDH. The level of GAPDH was set as 1 for Jurkat-MSCV, 0.81 for Jurkat-MSCV-IRF-4 and 2.83 for MT2 cells depending on the intensities. The two columns are the -fold increase (+) or decrease (7) in Jurkat-MSCV-IRF-4 and MT2 cell mRNA when compared to Jurkat-MSCV. (b) Protein extracts (50 mg) were obtained from the three cell lines used in RT -PCR analyses, Jurkat-MSCV, Jurkat-MSCV-IRF-4 and MT2. Samples were loaded on 10 or 15% SDS -PAGE, transferred to nitrocellulose and blotted with the different antibodies. Results from at least two separate immunoblots were quantified as described above. They were also quantified relative to the amount of actin amplified. The level of actin was set as 1 for Jurkat-MSCV and for Jurkat-MSCV-IRF-4 and 1.2 for MT2 cells depending on the intensities. The two columns are the -fold increase (+) or decrease (7) Several protein extracts (50 mg) were obtained from the three cell lines used in cDNA array analyses and RT -PCRs. Cyclin B1 protein expression was assessed in six immunoblots using different extract preparations. Quantification using the NIH program was calculated in the three cell lines relative to the amount of actin. (b) Cyclin B1 expression was assessed in two uninfected T cell lines, Jurkat and CEM, in three HTLV-1 infected T cell lines, MT2, C8166 and MT4 as well as in one HTLV-2 infected cell line, MOT. Equal amounts of WCE (50 mg) were loaded on a 10% SDS -PAGE, transferred to nitrocellulose and blotted with a-cyclin B1, a-IRF-4, a-Tax and a-actin successively. (c) Cyclin B1 expression was also assessed in peripheral blood lymphocytes from normal donors and ATL patients. WCE (120 mg) were loaded on a 10% SDS -PAGE, transferred to nitrocellulose and blotted with acyclin B1, a-IRF-4, a-Tax and a-actin successively. (d) In vitro CDC2 kinase assays were performed in the Jurkat-MSCV, Jurkat-MSCV-IRF-4, and in three HTLV-1 infected T cell lines, MT2, C8166 and MT4 in the presence of recombinant histone H1 as substrate. Whole cell lysates from the different cell lines were immunoprecipitated with an anti-CDC2 antibody. Immunoprecipitates were incubated with kinase buffer, 10 mCi of [g-32 P]ATP, inhibitor cocktail and recombinant histone H1 for 30 min at 308C. CDC2 protein levels (50 mg of WCE) were also assessed within the different cell lines with an a-CDC2 antibody. Actin levels were also analysed as a loading control
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CDC2 kinase activity in IRF-4 expressing cells
The normal G2-M checkpoint requires proper activation of the CDC2 kinase by cyclins B1 and A (Jackman and Pines, 1997; Johnson and Walker, 1999; O'Connor, 1997; Weinert, 1997) . A decrease in cyclin B1 in IRF-4 expressing cells could potentially lead to an abrogation in CDC2 kinase activity. Therefore, CDC2 kinase activity was assessed in Jurkat-MSCV, Jurkat-MSCV-IRF-4 as well as in the HTLV-1 infected T cell lines, MT2, MT4 and C8166 (Figure 3d ). An in vitro kinase assay was performed using immunoprecipitated CDC2 and recombinant histone H1 as substrate ( (Porter et al., 2000) , Upstate Inc., NY, USA). Interestingly, a moderate 1.6-fold decrease in CDC2 kinase activity was detected in Jurkat-MSCV-IRF-4 when compared to Jurkat-MSCV (Figure 3d , first panel, lanes 1 -2), while a greater 3 -6-fold decrease in CDC2 kinase activity was seen in all the HTLV-1 infected T cell lines compared to Jurkat-MSCV (Figue 3d, first panel, lanes 3 -5). These results suggest that CDC2 kinase activity is significantly decreased by cyclin B1 levels in the different cell lines (Figures 2b, 3a, b) . Immunoblot analysis of CDC2 and actin revealed equivalent amounts of protein ( Figure  3d , middle and bottom panels). CDC2 autophosphorylation as well as background phosphorylation was also assessed by performing similar in vitro kinase assays in the absence of the histone H1 substrate (Upstate Inc., NY, USA). No CDC2 autophosphorylation nor background phosphorylation was detected within the different extracts (Y Mamane, data not shown).
IRF-4 binds to multiple sites on the cyclin B1 promoter
To further study the IRF-4 mediated repression of cyclin B1 expression, the cyclin B1 promoter was analysed for IRF-4 binding sites using MathInspector software and several potential sites (ISRE and IRF-1/ IRF-2 sites) were identified within the promoter sequence (Figure 4a ). IRF-4 DNA binding to the putative IRF sites was assessed using eight oligonucleotide probes corresponding to the IRF sites ( Figure  4a,b) . Recombinant His-IRF-4 was incubated with the different DNA probes and protein-DNA complexes were detected by electrophoretic mobility shift assay. Complexes were detected with probes 2, 3 and 5 which are located between 71050 to 7521 bp in the cyclin B1 promoter (Figure 4c , lanes 2, 3 and 5). IRF-4-DNA complexes were also detected using probes 6 and 7, which localized to the region between the 521 and 287 nucleotides of the cyclin B1 promoter (Figure 4c , lanes 6 and 7).
IRF-4 downregulates the cyclin B1 promoter
Cyclin B1 promoter constructs containing different 5' promoter truncation were used in luciferase reporter assays to determine which region within the promoter was involved in IRF-4 repression (Figure 4b) .
Transfection of the cyclin B1 71050 bp promoter construct into Jurkat-MSCV, Jurkat-MSCV-IRF-4 and the HTLV-1 infected MT2 cells resulted in a twofold decrease in promoter activity in Jurkat-MSCV-IRF-4 and a 10-fold decrease in MT2 cells when compared to Jurkat-MSCV (Figures 4b and 5a) . The cyclin B1 7521 bp promoter activity was also repressed in Jurkat-MSCV-IRF-4 and MT2 cells, although to a lesser extent than the 1050 bp fragment (Figure 4b ). However, deletion of the cyclin B1 promoter to 7287 bp eliminated the IRF-4 mediated repression in the Jurkat-MSCV-IRF-4 and MT2 cells (Figures 4b and 5a ). Further deletions, 7220 and 7123 bp, did not show a decrease in promoter activity in the presence of IRF-4 (Figure 4b ) suggesting that the region between 7521 to 7287 bp contained the crucial sites for IRF-4 mediated repression of the cyclin B1 promoter. Strikingly, the cyclin B1 7123 bp construct displayed a dramatic increase in activity in MT2 cells ( Figure  4b ). Once all repressive IRF-4 sites are removed, transcription factors such as NF-Y involved in cyclin B1 expression are now free to activate transcription ( Figure 4a ). Based on EMSA results, IRF-4 binds to two of the three IRF sites present in the 7521 to 7287 bp region: site 6 (7469 to 7459 bp) and 7 (7413 to 7400 bp) (Figure 4c ). Mutation of these two IRF sites by replacing the conserved triple A repeat by TTT within the 7521 to 7287 bp region abrogated repression, thus demonstrating the importance of these sites in IRF-4 mediated repression of the cyclin B1 promoter ( Figure  5a ). These results further confirmed the importance of the 7521 to 7287 bp region in the IRF-4-mediated repression of the cyclin B1 promoter.
The IRF-4 mediated repression of cyclin B1 was also investigated in Cos7 cells which do not express endogenous IRF-4. The various cyclin B1 promoter constructs were cotransfected into Cos7 cells together with CDK2 and cyclin E expression plasmids, as well as with increasing amounts of IRF-4 in order to activate promoter activity (Katula et al., 1997) (Figure  5b ). Strikingly, a dose dependent decrease in promoter activity of the 71050 bp construct was detected with increasing amounts of IRF-4 (Figure 5b ). The 7521 bp promoter construct also showed decreased activity in the presence of increasing amounts of IRF-4 (Y Mamane, data not shown). However, IRF-4 expression did not repress the 7287 construct nor the 7220 and 7123 bp constructs (Y Mamane, data not shown). Moreover, the 7570 bp-IRF mutated cyclin B1 promoter was not repressed in response to increasing amounts of IRF-4 (Figure 5c ). These results confirm the importance of sites 6 and 7, located between 7521 and -287 nucleotides, in the IRF-4-mediated repression of cyclin B1 in T cells. Furthermore, point mutated sites 6 and 7 were unable to form an IRF-4-DNA complex in EMSA analysis (Figure 4c, lanes 9 -10) . Taken together, these results indicate that IRF-4 binding to sites 6 and 7 mediate cyclin B1 repression. Strong IRF-4-DNA binding
complexes were also detected with probes 3 and 5. These results are partially explained by the fact that probe 3 possesses two IRF binding sites and probe 5 is an excellent PU.1/IRF-4 half site (Brass et al., 1996; Eisenbeis et al., 1995; Marecki and Fenton, 2000) . No studies have yet to determine the best IRF-4 binding sequence and therefore difference in IRF-4 binding to several IRF sites may provide important information regarding a consensus sequence. Sites 6 and 7 of the cyclin B1 promoter were further analysed by multimerization (five copies each) and subcloned into the pGL3-enhancer vector previously used in the cyclin B1 promoter studies. Mutated multimerized site 6 and 7 constructs were also engineered by replacing the conserved triple A repeat by TTT thus abrogating the IRF site (Lin et al., 1999) .
These constructs were transfected into Jurkat-MSCV, Jurkat-MSCV-IRF-4 and MT-2, the HTLV-1 infected T cell line in order to determine the effect of IRF-4 expression on their activity. Once transfected into Jurkat-MSCV, the multimerized site 6 and 7 constructs as well as the mutants possessed on average a 1.5 -2-fold increase in activity compared to the empty pGL3-enhancer vector (Figure 6 ). Interestingly, transfection of the multimerized site 6 and 7 constructs into Jurkat-MSCV-IRF-4 and MT-2 cells led to a sharp decrease in luciferase reporter activity (Figure 6 ). The mutated constructs were also transfected into Jurkat-MSCV-IRF-4 and MT-2 cells. No decrease in the mutated reporter activities was detected in Jurkat-MSCV-IRF-4 or MT-2 cells (Figure 6 ). Together, these results demonstrate that IRF-4 binding to sites 6 and 7 
Discussion
In this study, we investigated the role of IRF-4 gene regulation in HTLV-1 infected T cells. These studies suggest an important role for IRF-4 in the repression of multiple genes involved in the mitotic checkpoint, actin cytoskeletal rearrangement, DNA repair, apoptosis, metastasis and immune recognition (Figure 7) . Such processes are often dysregulated in cellular transformation (Hanahan and Weinberg, 2000) and, in the context of HTLV-1 infection and the ATL phenotype, IRF-4 appears to repress several genes involved in DNA repair and chromosomal stability such as EB1, PCNA, RP-A, XRCC1 and SNF2b . pRL-TK (250 ng) coding for Renilla luciferase was also co-transfected in the cells and used as a measure of transfection efficiency. Twenty-four hours post-transfection, half of the samples were serum-starved for 24 h and then returned to normal media (with serum) for another 24 h before harvesting. An average of three to six experiments were performed. (b) The cyclin B1 promoter construct 71050 bp (250 ng) was cotransfected into Cos7 cells with CDK2 and cyclin E expression plasmids. The activated cyclin B1 71050 bp promoter construct was cotransfected with increasing amounts of IRF-4 (0.5, 1, 2, 4, 6 and 8 mg) and 50 ng of pRL-TK. Twenty-four hours posttransfection, the samples were serum-starved for 24 h and then returned to normal media (with serum) for another 24 h before harvesting. An average of three to six experiments were performed. Expression of all constructs in transfected cells was verified by immunoblot (Y Mamane, data not shown). (c) As described in (b) with the use of the cyclin B1 7570 bp-IRF mutant promoter construct (Table 1) (Bochkareva et al., 2000; Dianov et al., 1999; Duell et al., 2001; Muchardt and Yaniv, 2001; Vidal et al., 2001) . IRF-4 transcriptional downreglation of such genes would lead to an overall decrease in DNA repair and a subsequent increase in cellular mutations seen in HTLV-1 infected T cells, thus contributing to cellular transformation (Hanahan and Weinberg, 2000; Lengauer et al., 1998; Tsukasaki et al., 2000; Yoshida, 2001) (Figure 7) . IRF-4 also downregulates several pro-apoptotic genes such as NIP3, RhoB, ALG-2 calcium binding protein, GADD153 and DNAse II in HTLV-1 infected, ATL cells (Table 1) (Bruick, 2000; Lacana et al., 1997; Liu et al., 2001a,b; Lo et al., 1999; Maytin et al., 2001; Wang et al., 2000) . IRF-4 has a potential effect on immune recognition of HTLV-1 infected cells as well as on ATL spread and migration to peripheral tissues by modulating LFA-1, RhoA, Grb2, HSC70, RhoB, U-PAR and ezrin expression (Table 1) IRF-4 binds to sites within the cyclin B1 promoter and mediates repression. Five copies of site 6 and 7 of the cyclin B1 promoter were multimerized and subcloned into pGL3-enhancer. Mutated versions of the multimerized constructs were also generated by abrogating the IRF sites. The constructs were transfected into Jurkat-MSCV, Jurkat-MSCV-IRF-4 and MT2 cells (1610 6 cells/12-well plate). pRL-TK (250 ng) coding for Renilla luciferase was also co-transfected in the cells and used as a measure of transfection efficiency. Twenty-four hours post-transfection, the samples were serum-starved for 24 h and then returned to normal media (with serum) for another 24 h before harvesting. An average of three to six experiments were performed Seasholtz et al., 1999; Song et al., 2000; Tanaka et al., 1998) . Thus the overall effect of IRF-4 in HTLV-1 infected cells is to contribute to the emergence of the transformed phenotype, increased survival and ATL cell metastasis (Figure 7) . Recently, IRF-4 expression was also shown to increase during the clinical course of ATL, with expression levels elevated in patients with late stage, acute phase ATL (Imaizumi et al., 2001) . IRF-4 may thus be a potential therapeutic target; ablation of IRF-4 levels may lead to a decrease in HTLV-1 T cell viability and prevent the onset of acute phase ATL.
One of the genes identified by cDNA array, cyclin B1, was significantly decreased in Jurkat-MSCV-IRF-4 and in the HTLV-1 infected MT2 cells (Table 1) . Initially, RT -PCR and immunoblot analysis on cyclin B1 confirmed the results obtained by cDNA array (Figure 2 ). Protein-DNA interactions and promoter studies identified two IRF-4 binding sites in the 7521 to 7287 bp region of the cyclin B1 promoter that were necessary for IRF-4 mediated repression (Figures 4b, c and 5) . These experiments provide the first description of cyclin B1 as an IRF-4 repressed gene.
Cyclin B1 is involved in the G2/M and spindle checkpoints in cell cycle division (Jackman and Pines, 1997; Molinari, 2000; O'Connor, 1997) . Cyclin B1 expression increases at the end of S phase and is sustained through mitosis (Johnson and Walker, 1999) . It was previously demonstrated that cyclin B1 is positively regulated by USF, NF-Y, FoxM1 transcription factors (Cogswell et al., 1995; Katula et al., 1997; Leung et al., 2001) and negatively regulated by p53 (Innocente et al., 1999; Taylor and Stark, 2001) . High levels of cyclin B1 have been associated with an increased cell cycle progression while low levels of cyclin B1 seem to lead to a bypass of the mitotic checkpoint, thus contributing to aberrations in cellular division (Campbell et al., 2001; Jackman and Pines, 1997; Jin et al., 1998; Kasai et al., 2001; Neuveut and Jeang, 2002; O'Connor, 1997) . Indeed, cyclin B1 overexpression has been detected in human carcinomas arising from gastric, prostate, lung and esophageal cancer (Brien et al., 1998; Mashal et al., 1996; Murakami et al., 1999; Soria et al., 2000) . Some controversy does exist in the field, in that high levels of cyclin B1 have also been detected in cancer cells undergoing apoptosis (Chatterjee et al., 2000; Porter et al., 2000) .
In HTLV-1 leukemic T cells, a dramatic decrease in cyclin B1 levels was observed which may prevent the onset of proper mitotic checkpoint activities. Indeed, the activation of CDC2/cyclin B1 in cells usually results in DNA repair of chromosomal abnormalities, microtubule nucleation from the centrosomes and in spindle formation (Molinari, 2000) . The spindle is a highly organized and regulated structure which is responsible for chromosomal separation during cell division (Molinari, 2000) . Thus, the mitotic and spindle checkpoints are surveillance mechanisms that prevent the onset of anaphase and subsequent commitment to cellular division until chromosomes are repaired and properly aligned on a bipolar spindle. Disruption of this activity ultimately leads to chromosomal abnormalities such as breakage, duplication and mutations (Jackman and Pines, 1997; Jin et al., 1998; Lengauer et al., 1998; Nilsson and Hoffmann, 2000; O'Connor, 1997) . A fine regulatory balance in cyclin B1 levels must be maintained to prevent increased cell cycle progression and to allow for proper mitotic checkpoint activities, such as DNA repair, spindle formation and chromosomal segregation to occur (Jin et al., 1998; Kasai et al., 2001; Molinari, 2000) .
Mechanistically, a disruption in normal G2-M function has been shown previously to occur through the abrogation of CDC2 cell cycle-dependent kinase activity. Inactivation of CDC2 leads to the induction of endomitosis which is characterized by repeated S phases followed by abortive mitoses resulting in the generation of polyploid, multinucleated cells with aberrant cytokinesis (Jackman and Pines, 1997; Nilsson and Hoffmann, 2000; O'Connor, 1997; Weinert, 1997) . Inhibition of CDC2 can occur via CDK inhibitors; moreover, a decrease in cyclin B1, one of the primary activators of CDC2 (Johnson and Walker, 1999) , also leads to a decrease in CDC2 kinase activity in HTLV-1 infected cells (Figure 3d) . A decrease in cyclin B1 by IRF-4 would therefore abrogate the mitotic checkpoint, lead to improper chromosomal segregation and to the generation of polyploid/multinucleated cells. These effects on cyclin B1 expression levels and on the M checkpoint are independent of p53, which normally downregulates cyclin B1 expression (Innocente et al., 1999; Taylor and Stark, 2001 ), since HTLV-1 infected T cells lack p53 and p53-related proteins function (Kaida et al., 2000; Lemasson and Nyborg, 2001; PiseMasison et al., 1998 PiseMasison et al., , 2000a Yoshida, 2001 ). Interestingly, IRF-4 also downregulates another gene, EB1 (Table 1) , which is also involved in chromosomal stability. EB1 localizes to the mitotic spindle and cytoplasmic microtubules, where it regulates microtubule stability and the positioning of the mitotic spindle (Tirnauer and Bierer, 2000) .
Interestingly, other studies have demonstrated that the mitotic checkpoint is a recurring target of HTLV-1. The HTLV-1 viral Tax protein was shown to interact with human MAD1 (HsMAD1) protein and compromise its function by preventing homodimerization as well as heterodimerization with HsMAD2, thus leading to an inhibition of the M checkpoint (Campbell et al., 2001; Jin et al., 1998; Kasai et al., 2001; Neuveut and Jeang, 2002) . ATL cells are karyotypically abnormal and are frequently present as pleiomorphic multinucleated giant cells (Itoyama et al., 2001; Kamada et al., 1992; Sadamori, 1991; Sadamori et al., 1991; Tsukasaki et al., 2001; Yoshida, 2001) ; the TaxHsMAD1 interaction and the IRF-4 mediated downregulation of cyclin B1 and EB1 thus provide a molecular explanation for the HTLV-I-induced karyotypic abnormalities in ATL cells (Figure 7) .
Recently, a new role for cyclin B1 has been documented in apoptosis. Cyclin B1 protein levels were shown to increase in hematopoietic cells under-IRF-4 regulated genes in HTLV-1 infected T cells Y Mamane et al going apoptosis, and inhibition of this increase with antisense oligonucleotides abrogated apoptosis (Porter et al., 2000) . Moreover, ectopic expression of cyclin B1 was sufficient to induce apoptosis in hematopoietic cells. Porter et al. (2000) showed that cyclin B1 is both necessary and sufficient for g-radiation-induced apoptosis in lymphocytes. The pathways involved in g-radiation-induced apoptosis were p53-independent and therefore cyclin B1 is believed to be the critical component of this type of apoptosis. Another recent study has demonstrated that an increase in cyclin B1 expression in HIV-1 infected patient-samples leads to increased apoptosis of these cells (Cannavo et al., 2001) . Thus, a decrease in cyclin B1 by IRF-4 may also prevent apoptosis in HTLV-1 infected cells as well as inhibit the mitotic checkpoint activities (Figure 7) . The abrogation of the mitotic checkpoint by IRF-4 and by Tax (Jin et al., 1998; Kasai et al., 2001 ) has important consequences for treatment options for ATL patients. Current ATL treatments are largely ineffective and provide at most a 5% 4-year survival rate (Cann and Chen, 1996; Ohshima et al., 1999) . Recently, Kasai et al. (2001) reported that ATL cells are chemoresistant to microtubule inhibitors such as nocodazole. Conventional chemotherapeutic agents which target the G2-M checkpoint seem therefore ineffective in treating ATL. This failure is explained by the presence of an already abolished mitotic checkpoint, through the action of both IRF-4 and Tax in ATL cells. Since ATL cells are resistant to drugs that target the mitotic checkpoint, ATL patients may benefit from treatment with agents that target the G1-S checkpoint Jin et al., 1998; Kasai et al., 2001; Lemoine and Marriott, 2001; Neuveut and Jeang, 2002; Suzuki et al., 1996 Suzuki et al., , 1999 Yoshida, 2001) . Interestingly, the use of flavopiridol, a potent G1-S inhibitor (Senderowicz, 2000; Senderowicz and Sausville, 2000) significantly decreased HTLV-1 infected T cell viability (Kasai et al., 2001 ) and may be considered as potentially useful treatment for ATL patients.
The mechanisms of IRF-4 mediated gene repression have not been delineated. Several potential mechanisms are possible: (1) IRF-4 could affect transcription by directly binding to promoter sequences and preventing the formation of the transcription pre-initiation complex through competition with transcriptional activators for binding to the same sequences, (2) IRF-4 could also affect transcription indirectly by interacting with an already bound activator and inhibiting its effect through conformational changes or inhibition of its transactivation potential, (3) since IRF-4 is being expressed at high levels in HTLV-1 infected cells, IRF-4 may associate with other IRF-like activators and prevent their binding to gene promoters and thus repress transcription, or (4) IRF-4 may recruit histone deacetylases to promoters, thus rendering these promoters inaccessible to RNA pol II. Further promoter studies will prove insightful in determining the transcriptional repressive mechanism(s) utilized by IRF-4.
Materials and methods
Generation of IRF-4 stably-expressing cell line
The packaging cell line Phoenix Amphotropic (transformed human embryonic kidney cells) was purchased from ATCC with the written permission from Dr Gary Nolan (Stanford University). These cells were cultured in DMEM with sodium pyruvate and 10% FBS. The packaging cell lines were transfected as described by Dr Nolan's protocols (www.stanford.edu/group/nolan/phx helper free. html) with two vectors: pMSCVneo wt (no insert) and pMSCVneo-IRF-4. Fortyeight hours post-transfection, virus was harvested from the transfected packaging cell line and used to infect Jurkat T cells. They were infected twice, each 24-h infection in the presence of 16 mg/ml of polybrene (Sigma Inc.). Forty-eight hours post infection, the transduced Jurkat T cells were put under drug selection, G418/neomycin at a final concentration of 600 mg/l. After 2 weeks of selection by changing the media every 3 days, a polyclonal population resistant to neomycin emerged. Jurkat-MSCV-wt and Jurkat-MSCV-IRF-4 cells (20 millions each) were lysed in TNN (50 mM Tris-HCl, 200 mM NaCl, 0.5% NP-40) for 10 min on ice. Protein supernatants were recuperated after a 10 min spin at 14 000 g. Protein concentrations were determined using the Bradford reagent (Biorad Inc.) and a spectrophotometric assay. Protein extracts were loaded on a SDS -PAGE and transferred to a nitrocellulose membrane which was probed with a-IRF-4 antibody. The presence of high levels of IRF-4 protein was detected in Jurkat-MSCV-IRF-4 cells but not in Jurkat-MSCV-wt. A polyclonal population of these cells was used for RNA extraction needed for cDNA array analysis.
Cell lines and tissue culture
The uninfected Jurkat and CEM cells were cultured in RPMI with 10% FBS. HTLV-1 and HTLV-2 infected cells, MT2, MT4, C8166 and MOT were cultured as described by ATCC. Peripheral blood lymphocyte samples from ATL patients and normal donors were obtained from Dr Nazli Azimi (NCI, Bethesda, MD, USA). Normal and ATL extracts were derived from peripheral mononuclear cells obtained from normal donors and ATL patients. All ATL patients possessed high leukemic cell counts (five to six times higher levels of PBMCs compared to normal donors) and more than 50% of their peripheral T cells were leukemic. ATL is characterized by a monoclonal expansion of CD4+T cells (Tsukasaki et al., 2000) . Leukemic cells were a majority of CD4+, CD8-and CD25+ cells (Dr Nazli Azimi; NCI, Bethesda, MD, USA). Cos7 cells were cultured in DMEM supplemented with 10% fetal bovine serum and antibiotics.
RNA isolation for cDNA arrays
Cells (50 million) from the stably expressing cell line, Jurkat-MSCV-IRF-4 as well as the control cell line Jurkat-MSCV were collected and lysed using the denaturation solution supplied by the Clontech kit. Total RNA isolation was performed as described in the 'Atlas Pure Total RNA Labeling System' (#PT3231-1, Clontech Inc.). RNA purity and integrity was assessed by spectrophotometric analyses and agarose gel as described in the manual provided.
cDNA arrays analysis
Probe synthesis, hybridization and detection were performed as described in the 'Atlas Pure Total RNA Labeling System' IRF-4 regulated genes in HTLV-1 infected T cells Y Mamane et al (#PT3231-1, Clontech Inc.). Briefly, cDNA probe synthesis was performed in three steps: (1) Poly A mRNA from the two cell lines were annealed to biotinylated oligo dT, (2) Streptavidin coated magnetic beads were incubated with the RNA which bound to the biotinylated oligo dT and (3) after washing the beads using a magnet, the mRNAs were eluted of the beads and the cDNA probes were synthesized using gene-specific primers, reverse transcriptase and a-32P-dATP (as described by Clontech Inc.). The newly synthesized probes were used for hybridization and detection on two separate Atlas Human 1.2 Arrays (1176 characterized cDNA spotted on each; Clontech Inc.). Analysis of the membranes was possible through the use of the software 'AtlasImage 1.5' purchased from Clontech (#PT3381-1). A series of three separate experiments (RNA extraction, probe synthesis and hybridization) were performed in order to determine the genes regulated by IRF-4.
RT -PCR assays
RT -PCR was performed to confirm cDNA array analysis results with the use of the Clontech Inc. kit (K1402-2). Primer sequences for the potential IRF-4 regulated genes were purchased from Clontech Inc and synthesized by Invitrogen Inc. At first, the proper PCR conditions were assessed for each gene. 'Real-time' -PCR was performed on each gene from the three sample RNAs (Jurkat-MSCV-IRF-4, Jurkat-MSCV and MT2) by taking 5 ml aliquots from each PCR reaction at different cycles: 18, 23, 28, 33 and 38 (Clontech Inc.) . These aliquots were loaded on 2% agarose gel and visualized by ethidium bromide staining and UV shadowing (Y Mamane, data not shown). These initial PCRs permitted the determination of the appropriate number of PCR cycles needed for the amplification of each gene within a linear and non-saturated range. Listed below are the number of PCR cycles used for each gene amplification: HSC70=28, RhoA=23, RP-A=28, ERBB3=33, GRB2=28, 14-3-3Z=28, cyclin B1=28, EB1= 28, PCNA=28, NIP3=28, LFA-I=28 and GAPDH=23. The above mentioned conditions were then used for RT -PCR analyses in the presence of a-32P-dCTP. RT -PCR samples (5 ml) were loaded on 4% polyacrylamide gels, dried and exposed to film.
Western blot analysis
Whole cell extracts (50 mg) were fractionated by 10 -15% SDS -PAGE and transferred to Hybond transfer membrane (Biorad Inc.). The membrane was blocked in 5% milk for 1 h and probed overnight at 48C with the appropriate antibody at dilutions between 1 : 200 to 1 : 2000. The signal was detected with secondary antibodies conjugated to horseradish peroxidase at a dilution of 1 : 1000 and developed with chemiluminescence substrate (Amersham Inc.). The different antibodies were purchased or received from: a-IRF-4/ICSAT/Pip (Santa Cruz Inc., Zymed Inc), aTax (Dr WC Greene, Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA, USA), a-HSC70 (Calbiochem Inc.), a-RhoA (Santa Cruz Inc. and Dr R Desrosiers, UQAM, Montreal, Canada), a-RP-A (Dr T Kelly, John Hopkins University, Baltimore, MD, USA), a-ERBB3 (Santa Cruz Inc.), a-14-3-3 (Transduction Laboratories Inc.), a-Cyclin B1 (Dr JM Lee, HRCC, Hamilton, Canada), a-EB1 (Transduction Laboratories Inc.), a-PCNA (Transduction Laboratories Inc.), a-LFA-1 (Transduction Laboratories Inc.), a-NIP3 (Dr R Bruick, University of Texas, USA) and a-actin (Chemicon Inc.).
CDC2 in vitro kinase assay
In vitro kinase assay was performed using 500 mg of whole cell extracts in fresh lysis solution: 20 mM Tris HCL pH 7.5, 200 mM NaCl, 0.5% NP-40, protease inhibitors-leupeptin, pepstatin A, aproptinin, 1 mM sodium orthovanadate, 20 mM sodium fluoride, 30 mM B-glycerophosphate. CDC2 antibody (Upstate Inc., NY, USA; 1 mg per immunoprecipitation) was crosslinked to protein G Sepharose beads . Kinase assay reactions were performed by following the instructions provided with the cdk1/cdc2 kinase assay kit (Upstate Inc. NY, USA). Briefly, protein extracts were incubated with anti-cdc2 crosslinked antibody for 4 h at 48C. Beads were washed 36in TNN (lysis solution) and 10 ml of recombinant H1 substrate (2 mg/ml), inhibitor cocktail (20 mM PKC inhibitor peptide, 2 mM PKA inhibitor peptide and 2 mM Compound R24571) and Assay Dilution Buffer I were added to the washed beads. A mixture of 9 ml of Mg/ ATP cocktail and 1 ml of [g-32 P]ATP (10 mCi) were added to each kinase reaction. The reaction was incubated at 308C for 30 min and stopped by adding 6 ml of 56SDS loading dye. Reactions were loaded on 12% SDS -PAGE gels. After migration, the gel was fixed in 10% acetic acid/10% methanol for 15 min at room temperature. The gel was stained with Coomassie blue and destained to ensure equal loading of the recombinant histone H1 substrate in all reactions (Y Mamane, data not shown). Gels were soaked in 10% glycerol for 30 min, dried and exposed to film. Immunoprecipitated complexes were also resolved on 12% SDS -PAGE and immunoblotted with an a-CDC2 antibody to ensure equal levels of CDC2 immunoprecipitation (Y Mamane, data not shown). CDC2 autophosphorylation as well as background phosphorylation was also assessed by performing similar in vitro kinase assays in the absence of the histone H1 substrate (Upstate Inc., NY, USA). No CDC2 autophosphorylation nor background phosphorylation was detected within the different extracts (Y Mamane, data not shown). In vitro kinase assays were performed five times on different cellular extracts.
Constructs
The cyclin B1 71050 bp construct was obtained from Drs JM Lee and SA Innocente (Innocente et al., 1999) . The deleted cyclin B1 promoter constructs, CDK2 and cyclin E expression plasmids were obtained from Dr W Taylor (Taylor et al., 1999; Taylor and Stark, 2001 ). The 7570 bp IRF mutant (sites 6 and 7 abrogated) was generated by overlap PCR, subcloned into pGL3-enhancer (SacI/HindIII, Promega Inc.) and sequenced (Amplicon Express Inc.). Listed below are the primers used for the overlap PCR. The IRF sites were abrogated by replacing the conserved triple A repeat by TTT (underlined) . A=5'-GATC-GAGCTCAAAACCCTAAATTCAGTTCCC-3', B=5'-AGT-GTTGCACACAAACCAAAACTACGGTAGCAGCAATA-ATATAGTTCATGA AAGGCTTTAATAGACATTCAAA-CAAAAGATCGTTGCAACAACTCTCTG-3', C=5'-GTT-GCAAC GAT CTTTTGTTTGAA TGTCTATTAA AGCCT-TTCATGAACTATATTATTGCTGCTACC GTAGTTTTG-GTTTGTGTGCAACACTAGATCCAAA-3', D=5'-GATC-AAGCTTCATGGCTTCCTCTTCACCA-3'.
Further luciferase reporter constructs were engineered by multimerizing sites 6 and 7 (five copies each) and subcloning into pGL3-enhancer (SacI/HindIII, Promega Inc.). Mutated multimerized site 6 and 7 constructs were also engineered by replacing the conserved triple A repeat by TTT thus abrogating the IRF sites .
Luciferase assays
Transient expression assays using luciferase constructs were carried out in Jurkat-MSCV, Jurkat-MSCV-IRF-4 and MT-2. These cells were cultured in RPMI 1640 media (Wisent Inc.) supplemented with 10% fetal bovine serum and antibiotics. Cells (1610 6 ) were seeded in 12-well plates and transfected with 2 mg of reporter plasmid (Cyclin B1 promoter constructs) and 250 ng of pRL-TK (renilla) using Fugene reagent (Roche Inc.). Twenty-four hours posttransfection, cells were serum starved for 24 h. Serum was then added back to the cells for another 24 h in culture before harvesting. Serum starvation was used to enhance luciferase production in a synchronous fashion to correlate with the cell cycle dependent expression of cyclin B1. Cells were harvested 60 h post-transfection and luciferase activity was measured by the dual luciferase assay system (Promega Inc.). Luciferase activities represent an average obtained from three to six independent experiments.
Luciferase assays carried out in Cos7 cells were transiently transfected with lipofectamine reagent (CLT Inc.). Cos7 cells (3610 5 cells/5 cm plate) were seeded at 60% confluency and transfected with 250 ng of the different cyclin B1 promoter constructs, 2 mg of CDK2/cyclin E (provided by Dr W Taylor), increasing amounts of IRF-4 (0.5, 1, 2, 4, 6 and 8 mg) and 50 ng of pRL-TK. Twenty-four hours posttransfection, cells were serum starved for 24 h. Serum was then added back to the cells for another 24 h in culture before harvesting. Cells were harvested 60 h post-transfection and luciferase activity was measured by the dual luciferase assay system (Promega Inc.). Luciferase activities represent an average obtained from three to six independent experiments. Expression of the different constructs in the luciferase cell extracts was confirmed by Western blot analysis (Y Mamane, data not shown).
Electrophoretic mobility shift assay
Recombinant his-tagged IRF-4 (95% purity, 100 ng/ml) used in EMSA was produced as described previously . Cyclin B1 promoter sequences used for dsDNA probes are listed below. Potential ISREs and IRF-1/IRF-2 binding sites are underlined: Probe 1=5'-AGAAGCCAAA AAGAACCCTCTTGTTT TTCTTTGGA-TCT-3', Probe 2=5'-GGGTAAAATGTCTTTTTGTTTAG-TTTTTCCTGA-3', Probe 3=5'-ATTTCCAAATAGAAA-GCTAAAACAAACAAAACAAT-3', Probe 4=5'-CAAAA-CAATTGCCCTTGGGAAACTGGAC-3', Probe 5=5'-CC-TCCCCCTCCAAAAAAAAAAAACCCTAAAT-3', Probe 6=5'-TGTTGCAAC GATC AAATGAAAGAATGTCTA-3', Probe 7=5'-GCTACCGTAGAAATGGAAAGTGTGCAA-CAC-3', Probe 8=5'-GTGCAACACTAGATCCAAAAC-TACTTT-3'. Probes 3 and 4 as well as probes 7 and 8 do share some overlap as seen in bold characters. Mutated probes 6 and 7 were also generated by replacing the conserved triple As by TTT (underlined): Probe 6Mut=5'-TGTTGCAAC-GATCTTTTGTTTGAATGTCTA-3', Probe 7Mut=5'-GCT-ACCGTAGTTTTGGTTTGTGTGCAACAC-3' .
Probes were made double-stranded and gel purified before being labeled with radioactive [g-32 P]ATP. Recombinant IRF-4 (200 ng) was incubated in 10 mM Tris pH 7.5, 50 mM NaCl, 1 mM DTT, 1 mM EDTA, 5% glycerol and 0.2 mg of poly dI/dC on ice for 30 min. Protein-DNA interactions occurred with the addition of radioactive dsDNA probes (100 000 c.p.m.) for 15 min at room temperature. Complexes were run on 5% acrylamide, 0.56TBE native gels, dried and exposed to film.
